351 related articles for article (PubMed ID: 19040393)
1. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.
Chen Y; Huang L
Expert Opin Drug Deliv; 2008 Dec; 5(12):1301-11. PubMed ID: 19040393
[TBL] [Abstract][Full Text] [Related]
2. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
Hong CA; Nam YS
Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
[TBL] [Abstract][Full Text] [Related]
3. Strategies for in vivo siRNA delivery in cancer.
Sanguino A; Lopez-Berestein G; Sood AK
Mini Rev Med Chem; 2008 Mar; 8(3):248-55. PubMed ID: 18336345
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.
Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C
Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817
[TBL] [Abstract][Full Text] [Related]
5. A review of the current status of siRNA nanomedicines in the treatment of cancer.
Resnier P; Montier T; Mathieu V; Benoit JP; Passirani C
Biomaterials; 2013 Sep; 34(27):6429-43. PubMed ID: 23727262
[TBL] [Abstract][Full Text] [Related]
6. Small Interfering RNAs and their Delivery Systems: A Novel Powerful Tool for the Potential Treatment of HIV Infections.
Bolhassani A; Milani A
Curr Mol Pharmacol; 2020; 13(3):173-181. PubMed ID: 31760929
[TBL] [Abstract][Full Text] [Related]
7. Advances in siRNA delivery in cancer therapy.
Singh A; Trivedi P; Jain NK
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
[TBL] [Abstract][Full Text] [Related]
8. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
Akhtar S; Benter I
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
[TBL] [Abstract][Full Text] [Related]
9. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional nanocarrier based on clay nanotubes for efficient intracellular siRNA delivery and gene silencing.
Wu H; Shi Y; Huang C; Zhang Y; Wu J; Shen H; Jia N
J Biomater Appl; 2014 Apr; 28(8):1180-9. PubMed ID: 23985535
[TBL] [Abstract][Full Text] [Related]
11. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.
Shahzad MM; Mangala LS; Han HD; Lu C; Bottsford-Miller J; Nishimura M; Mora EM; Lee JW; Stone RL; Pecot CV; Thanapprapasr D; Roh JW; Gaur P; Nair MP; Park YY; Sabnis N; Deavers MT; Lee JS; Ellis LM; Lopez-Berestein G; McConathy WJ; Prokai L; Lacko AG; Sood AK
Neoplasia; 2011 Apr; 13(4):309-19. PubMed ID: 21472135
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic siRNA: principles, challenges, and strategies.
Gavrilov K; Saltzman WM
Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of RNA interference against cancer.
Takeshita F; Ochiya T
Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
[TBL] [Abstract][Full Text] [Related]
15. Research progress on siRNA delivery with nonviral carriers.
Gao Y; Liu XL; Li XR
Int J Nanomedicine; 2011; 6():1017-25. PubMed ID: 21720513
[TBL] [Abstract][Full Text] [Related]
16. Delivery strategies and potential targets for siRNA in major cancer types.
Lee SJ; Kim MJ; Kwon IC; Roberts TM
Adv Drug Deliv Rev; 2016 Sep; 104():2-15. PubMed ID: 27259398
[TBL] [Abstract][Full Text] [Related]
17. Quantum rods as nanocarriers of gene therapy.
Aalinkeel R; Nair B; Reynolds JL; Sykes DE; Law WC; Mahajan SD; Prasad PN; Schwartz SA
Drug Deliv; 2012 May; 19(4):220-31. PubMed ID: 22643056
[TBL] [Abstract][Full Text] [Related]
18. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
Joo MK; Yhee JY; Kim SH; Kim K
J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
[TBL] [Abstract][Full Text] [Related]
19. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
Mainini F; Eccles MR
Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
[TBL] [Abstract][Full Text] [Related]
20. Progress on ocular siRNA gene-silencing therapy and drug delivery systems.
Jiang J; Zhang X; Tang Y; Li S; Chen J
Fundam Clin Pharmacol; 2021 Feb; 35(1):4-24. PubMed ID: 32298491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
